An Expanded Access Programme with Iressa for patients with Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Study identifier:1839IL/0052

ClinicalTrials.gov identifier:NCT00684385

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An International Expanded Access Clinical Programme with ZD1839 (IRESSA) for Patients with Advanced Non-small Cell Lung Cancer(NSCLC) and patients with Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H&NC)

Medical condition

Non Small Cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

ZD1839

Sex

All

Actual Enrollment

265

Study type

Expanded Access

Age

18 Years - 130 Years

Date

Study Start Date: -
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: N/A
Endpoint Classification: None
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria